Kyle Haraldsen

Kyle Haraldsen joined Viridian as Chief Technical Operations Officer in 2024. He has over 20 years of development and operations experience in the biopharmaceutical industry. Most recently, Kyle served as the Chief Technology Officer at Lyndra Therapeutics, a drug delivery company developing the first long-acting oral drug platform. While there he led the product and platform R&D activities for the LYNX™ drug delivery platform and manufacturing strategy. Prior to Lyndra, Kyle served as Chief Technical Operations Officer at Saniona, where he established the technical operations department and led efforts to develop a complex long-acting multi-product formulation of their lead asset. Before Saniona, he held roles of increasing responsibility in technical operations and manufacturing at AMAG Pharmaceuticals, most recently servicing as Vice President, Technical Operations & Project Management.

Kyle holds a B.S. in chemical engineering from Northeastern University. He has served as an advisory board/council member for the Friends of Parkinson’s, Dearborn STEM Academy, and Northeastern’s Biopharmaceutical Analysis Training Lab (BATL) and Chemical Engineering Industrial Advisory Board (IAB).